REAL WORLD ADHERENCE, PERSISTENCE, RELAPSE AND MULTIPLE SCLEROSIS SYMPTOMS AMONG PATIENTS TREATED WITH ORAL DISEASE-MODIFYING THERAPIES

被引：0
|
作者：
Leist, T. [1 ]
Le, H. [2 ]
Verma, S. [3 ]
Cole, M. [4 ]
Afolabi, M. [3 ]
Tsai, W. L. [3 ]
Keenan, A. [5 ]
机构：
[1] Jefferson Univ, Philadelphia, PA USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] STATinMED Res Inc, Plano, TX USA
[4] Janssen Global Serv LLC, Southampton, PA USA
[5] Janssen Global Serv LLC, Titusville, NJ USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PB3
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] RELAPSE-RELATED OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH FIRST-LINE DISEASE-MODIFYING THERAPIES
    Cohan, S.
    Corvino, F. A.
    Oliveri, D.
    Heo, J. H.
    Wang, W.
    Tencer, T.
    VALUE IN HEALTH, 2019, 22 : S737 - S737
  • [42] REAL-WORLD OUTCOMES AND MEDICATION ADHERENCE TO DISEASE MODIFYING THERAPIES (DMTS) AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS)
    Grassi, D. M.
    Graham, J.
    Ye, X.
    Maeng, D.
    Frusciante, K.
    Nathanson, D. C.
    Burton, M.
    Wright, E.
    Gomes, J.
    Bao, Y.
    VALUE IN HEALTH, 2018, 21 : S203 - S203
  • [43] Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?
    Vijayshree Yadav
    Dennis Bourdette
    Current Neurology and Neuroscience Reports, 2010, 10 (5) : 333 - 335
  • [44] Characteristics of multiple sclerosis patients treated with disease-modifying therapies in Puerto Rico
    Chia, J.
    Nunez, M.
    Hernandez, H.
    Jimenez, G.
    Stephen, S.
    Hashemi, L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 773 - 774
  • [45] Characteristics of Multiple Sclerosis Patients Treated With Disease-Modifying Therapies in Puerto Rico
    Chia, Joanne
    Nunez, Manuel
    Hernandez, Hector
    Jimenez, Gustavo
    Stephen, Sibin
    Hashemi, Lobat
    NEUROLOGY, 2019, 92 (15)
  • [46] Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review
    Yoon, Ee Ling
    Cheong, Wing Loong
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 104 - 108
  • [47] Disease-modifying therapies for multiple sclerosis
    De Angelis, Floriana
    John, Nevin A.
    Brownlee, Wallace J.
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [48] Multiple sclerosis and disease-modifying therapies
    Minen, Mia T.
    Karceski, Steven
    NEUROLOGY, 2011, 77 (04) : E26 - E26
  • [49] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [50] Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis
    Krysko, Kristen M.
    Graves, Jennifer S.
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Rutatangwa, Alice
    Aaen, Gregory
    Belman, Anita
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu S.
    Harris, Yolanda
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Moodley, Manikum
    Ness, Jayne
    Rodriguez, Moses
    Rose, John
    Schreiner, Teri
    Tillema, Jan-Mendelt
    Mas, Michael Waltz
    MStat, T. Charles Casper
    Waubant, Emmanuelle
    ANNALS OF NEUROLOGY, 2020, 88 (01) : 42 - 55
12345